Recently, an FGF21 analog, LY2405319, has been developed and used in a randomized, placebo-controlled, double-blind trial in patients with obesity and type 2 diabetes. This evidence concerns the gene FGF21 and obesity due to melanocortin 4 receptor deficiency.